



Name	Pil Soo Sung
Affiliation	The Catholic University of Korea
Country	Republic of Korea
Major Field	Hepatology, Liver cancer

Educational Background

Pil Soo Sung, MD, PhD, is a Professor of Internal Medicine at The Catholic University of Korea and a clinician–scientist at Seoul St. Mary’s Hospital. Trained in hepatology (MD 2007; MS 2011) and immunology (PhD, KAIST 2016),

Professional Experience

Dr. Sung investigates antiviral and tumor immunity across the HBV–HCC spectrum. His team established direct ex vivo profiling of HBV-specific CD8⁺ T cells in so-called “immune-tolerant” patients, enabling precise immune monitoring, and revealed an IgA–myeloid checkpoint that shapes intrahepatic inflammation, fibroblast remodeling, and responses to immunotherapy. Recent publications include Hepatology, Liver Cancer, and Journal for ImmunoTherapy of Cancer; he also co-authored a Nature Reviews Immunology overview of immunity in viral hepatitis.

Main Scientific Publications

- Direct ex vivo detection/phenotyping of HBV-specific CD8⁺ T cells in “immune-tolerant” patients (Front Immunol 2019).
- Novel HBV genotype C mouse model establishment (Viruses 2024)
- Defined intrahepatic IgA⁺/PD-L1high monocytes as an immunosuppressive axis linked to HCC development and immunotherapy (J Immunother Cancer 2022).
- Demonstrated IgA immune-complex–driven polarization of cancer-associated fibroblasts in HCC (Hepatology 2024).
- Established on-treatment peripheral T-cell biomarkers for atezolizumab–bevacizumab in HCC (Liver Cancer 2024/2025).
- Reported reactivation of resolved HBV after daratumumab, informing antiviral prophylaxis (Clin Infect Dis 2021).